Nutrien (TSX:NTR): Assessing Valuation After Spotlight at Soil Health Conference

Nutrien (TSX:NTR) took the stage at the Soil Health Conference in Calgary this week, drawing extra attention from investors and the broader agriculture sector. Company presentations at events like these can sometimes provide fresh insights into strategy or upcoming innovations, even if all the details aren't immediately disclosed. Right now, many are wondering if something meaningful was hinted at, or if this is just another momentary spotlight for the stock.

It has been an interesting stretch for Nutrien, with modest price changes over the past month but a notable rally since the start of the year. Over the past year, investors have seen the stock climb 30%, easily outpacing much of the market. However, its longer-term trajectory has been bumpier. The combination of recent conference remarks and year-to-date performance is leading some to wonder if momentum is finally turning after a sluggish few quarters.

So, after all this movement, is Nutrien trading at a bargain, or is the market already anticipating the next wave of growth?

Most Popular Narrative: 8.5% Undervalued

The most widely followed narrative sees Nutrien as undervalued by nearly 9%, pointing to a disconnect between the current share price and expectations for future growth and market stability.

The drive to maximize yields per acre due to climate change, shrinking arable land, and erratic weather is boosting fertilizer adoption and incentivizing precision agriculture. Nutrien's investments in automation, precision agriculture, and efficiency position it to capture higher-margin, premium sales and expand net margins over time.

Want to discover what ambitious growth plans underpin that price target? The narrative hints at impressive financial improvements and a sharply higher profit margin on the horizon. Curious how this scenario breaks down in analyst projections and what bold assumptions drive their valuation? Explore the full breakdown to uncover the story behind this calculated upside.

Result: Fair Value of $86.17 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent regulatory pressures or a faster shift toward organic and alternative crop solutions could easily undermine Nutrien's long-term growth story.

Find out about the key risks to this Nutrien narrative.

Another View: Our DCF Model Perspective

Taking a different angle, the SWS DCF model also finds Nutrien undervalued, reinforcing the previous view. Still, every method uses its own assumptions. Could the real value land somewhere in the middle?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nutrien for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Nutrien Narrative

Of course, if you feel differently or prefer to dig into the numbers yourself, you can put together your own story quickly and see how the details stack up. Do it your way.

A great starting point for your Nutrien research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Smart investors always keep fresh options on their radar. Expand your portfolio by exploring these powerful stock search tools that highlight industry movers, reliable dividend payers, and tomorrow’s big disruptors.

• Find companies that offer steady passive income by targeting businesses with reliable yields using our dividend stocks with yields > 3%.
• Focus on undervalued stocks with potential upside using our handpicked undervalued stocks based on cash flows.
• Discover high-growth opportunities by seeking out innovators leading in healthcare and artificial intelligence with our healthcare AI stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com